
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
We’re still hearing from you about our second annual Issues & Attitudes Survey, such as these comments from your pediatric colleague in Succasunna, NJ.
Click here to see the complete results of our 2014






